AmpliMed Malignant Melanoma, Amplimed is a cancer research chemotherapy corporation with a drug class that features novel mechanisms of action that can defeat MDR and some toxicities

Malignant Melanoma

Protocol AMP-008

AMP-008 is a planned randomized Phase II comparison of Amplimexon® plus DTIC® versus DTIC® alone. It is currently under development. Further information on this protocol will be available in the near future.